



FUND A:

Global Strategic Research

Price Tag: USD 12 Million

Our Scientific Advisory Committee and the Research Grants Review Committee select research proposals according to NIH criteria that identify best near-term chances for advancing a cure.

FUND B:

Multi-Institutional Network (WM-NET)

Innovative clinical trial coordination

Price Tag: USD 2.3 Million

WM-NET counters a fundamental rare-disease challenge. This US-based think tank develops common scientific clinical trials and enrolls patients collectively across 18 leading hospitals.

FUND C:

Next-Generation Researcher

Price Tag: USD 2.3 Million

Research of post-doctoral fellows and junior faculty is funded, deepening their commitment and expertise in the B-cell malignancy field. Awardees work with WM mentors.

Opportunity Funds A, B, C:

Milestone reports for each fund are sent to investors every six months. Expect to know about your return on investment.

The Scientific Advisory Committee:

WM experts from the United States, Germany, Greece, the United Kingdom, the Netherlands, and Sweden.

NIH rating for proposals:

This rating is based on overall impact, significance, investigator credentials, innovation, well-reasoned approach, and unique features of the scientific environment that add benefit.

JOIN THE FIGHT

Waldenstrom's Macroglobulinemia (WM)

ACCELERATE THE CURE:

Research Goal of USD 16.6 Million through 2028

The Scientific Advisory Committee

Stephen Ansell, MD, Co-Chair

Mayo Clinic, Rochester, MN

Steven Treon, MD,

Co-Chair—Dana Farber Cancer Institute, Boston, MA

James R. Berenson, MD

Institute for Myeloma & Bone Cancer Research, Hollywood, CA

Christian Buske, MD

Professor, Institute of Experimental Cancer Research, Ulm, Germany

Jorge Castillo, MD

Dana Farber Cancer Institute, Boston, MA

Morton Coleman, MD

Weill Cornell Medical College, New York, NY

Meletios A. Dimopoulos, MD

Alexandra Hospital, Athens, Greece

Stanley Frankel, MD

Columbia University, New York, NY

Marie Gertz, MD

Mayo Clinic, Rochester, MN

Irene Ghobrial, MD

Dana-Farber Cancer Center, Boston, MA

Zachary Hunter, PhD

Bing Center for WM; Dana Farber Cancer Institute, Boston, MA

Prashant Kapoor, MD, FACP

Mayo Clinic, Rochester, MN

Efstathios Kastritis, MD

National & Kapodistrian U. of Athens, School of Medicine, Greece

Eva Kimby, MD, PhD

Karolinska Institute and Hematology Centre at Karolinska University Hospital, Stockholm, Sweden

Monique Minnema, MD

Universiteit Utrecht, Utrecht, Netherlands

Gwen L. Nichols, MD

Executive VP of the Leukemia & Lymphoma Society, New York, NY

Roger Owen, MD

Institute of Oncology, Leeds, United Kingdom

Lia Palomba, MD

Memorial Sloan Kettering Cancer Center, New York, NY

Surinder Sahota, PhD

University of Southampton, United Kingdom

Marcel Spaargaren, PhD

Amsterdam University Medical Center, Netherlands

Sheeba Thomas, MD

MD Anderson Cancer Center, Houston, TX